Four years after winning an FDA approval for Koselugo to treat children with the rare disorder neurofibromatosis type 1 (NF1) ...
Neuralink, Elon Musk’s brain-computer venture, and rivals like Max Hodak’s Science, are chasing advances in technology that ...
Kamen and Sequel Medtech CEO Alan Lotvin say they are offering greater precision in insulin delivery with new pump technology ...
Nevro's HFX iQ spinal cord stimulator earned the European Union's CE mark, the company said Nov. 12.
Revolutionizing Disease Detection with Point-of-Care Health Screenings: Vitazi.ai Leads in Oculomics
SANTA FE, N.M., Nov. 13, 2024 /PRNewswire/ -- Vitazi.ai, a leader in the field of oculomics, is transforming healthcare with an innovative approach to early disease interception through point-of-care ...
In-shoe sensors, AI and biomarkers will monitor muscular dystrophy and atrophy in children, adolescents and adults — with ...
Amicus Therapeutics’ first oral drug for the rare condition Fabry disease has been approved by the FDA ... the FDA said it required a third phase 3 trial to test the drug's gastrointestinal ...
VIVOLTA, the medical electrospinning solutions provider, has partnered with Neurochase, to make micro-catheters to deliver therapies to the brain.
Discover how Remedy Logic's FDA-cleared RAI program, powered by AI, is revolutionizing spine MRI interpretation for radiologists and patients.
Researchers wishing to appeal against the decision of one of the Research Ethics Panels (REP) should, in the first instance, appeal the decision with the Chair of the REP. The Chair will review the ...
(IN BRIEF) Michael Schmid has been elected as the new President of Eurojust, taking office on 15 November 2024 for a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback